Table 3.

Use of statin medication in 22,936 patients (cases) with primary UBC diagnosed between 2005 and 2014 and in 229,326 matched control individuals

		All cases and control individuals			Cases and controls without diabetes mellitus
Variables		%		OR (95% CI)	%		OR (95% CI)
	Case	33.8	7754 of 22,936	1.23 (1.19–1.27)	28.1	5299 of 18,866	1.20 (1.16–1.25)
	Controls	29.8	68,247 of 229,326	p<0.0001	25.4	48,034 of 193,202	p<0.0001
Age at diagnosis (year)
<65	Case	20.4	973 of 4764	1.36 (1.26–1.47)	15.5	626 of 4048	1.35 (1.23–1.48)
	Control	16.1	7659 of 47,640	p<0.0001	12.2	5147 of 42,272	p<0.0001
65–74	Case	37.3	2736 of 7341	1.23 (1.17–1.29)	29.8	1739 of 5835	1.17 (1.10–1.25)
	Control	32.9	24,135 of 73,410	p<0.0001	26.8	16,197 of 60,485	p<0.0001
75–79	Case	42.7	1721 of 4030	1.26 (1.17–1.35)	36.5	1170 of 3207	1.21 (1.12–1.31)
	Control	37.6	15,154 of 40,300	p<0.0001	32.4	10,688 of 32,957	p<0.0001
≥80	Case	34.2	2324 of 6801	1.16 (1.09–1.22)	30.5	1764 of 5776	1.17 (1.10–1.24)
	Control	31.3	21,299 of 67,976	p<0.0001	27.8	16,002 of 57,488	p<0.0001
Muscle-invasive UBC
No	Case	35.1	6087 of 17,344	1.31 (1.26–1.35)	29.1	4112 of 14,117	1.27 (1.22–1.32)
	Control	29.8	51,734 of 173,433	p<0.0001	24.9	36,326 of 146,129	p<0.0001
Yes	Case	29.9	1648 of 5508	1.02 (0.96–1.08)	25.1	1174 of 4683	1.02 (0.95–1.10)
	Control	29.6	16,297 of 55,053	p=0.60	24.9	11,562 of 46,379	p=0.54
Gender
Male	Case	35.8	6147 of 17,182	1.25 (1.21–1.30)	29.8	4131 of 13,860	1.23 (1.18–1.28)
	Control	31.2	53,625 of 171,786	p<0.0001	26.1	37,195 of 142,731	p<0.0001
Female	Case	27.9	1607 of 5754	1.15 (1.08–1.23)	23.3	1168 of 5006	1.13 (1.05–1.22)
	Control	25.4	14,622 of 57,540	p<0.0001	21.5	10,839 of 50,471	p=0.001
TNM/grade
Ta, G1–2	Case	34.6	3460 of 10,009	1.34 (1.28–1.40)	28.4	2305 of 8109	1.29 (1.22–1.37)
	Control	28.8	28,873 of 100,090	p<0.0001	23.8	20,183 of 84,635	p<0.0001
Ta, G3	Case	39.7	435 of 1096	1.45 (1.27–1.65)	34.9	317 of 908	1.51 (1.30–1.76)
	Control	31.9	3498 of 10,960	p<0.0001	26.8	2460 of 9180	p<0.0001
TIS	Case	38.9	235 of 604	1.52 (1.26–1.83)	33.4	164 of 491	1.54 (1.24–1.91)
	Control	30.5	1843 of 6040	p<0.0001	25.4	1281 of 5051	p=0.0001
T1, G1–3	Case	35.2	1763 of 5011	1.20 (1.13–1.28)	29.4	1200 of 4086	1.16 (1.08–1.25)
	Control	31.5	15,797 of 50,103	p<0.0001	26.6	11,169 of 42,015	p<0.0001
T2–T4	Case	30.5	1374 of 4501	1.04 (0.97–1.11)	25.8	980 of 3804	1.05 (0.97–1.14)
	Control	29.8	13,404 of 44,983	p=0.28	25.2	9564 of 37,942	p=0.25
N+ and/or M+	Case	27.2	329 of 1210	0.90 (0.79–1.04)	21.5	225 of 1046	0.86 (0.73–1.01)
	Control	29.0	3514 of 12,100	p=0.16	24.1	2437 of 10,107	p=0.076

The Cochran-Mantel-Haenszel test was used to evaluate odds ratios and confidence intervals in all cases and controls, subgroup of cases, and control individuals without diabetes, respectively. Subgroup analysis was done based on age at diagnosis, whether muscle invasive UBC, and gender and grouped on TNM stage and tumor grade.